复发性着床失败是否存在?123987例患者中五次连续整倍体囊胚移植的患病率与结局
该国际多中心回顾性研究在25家诊所2012年1月至2022年12月间筛查123987例患者,其中105例(0.085%)在三次整倍体囊胚移植失败后接受额外移植;第四次与第五次整倍体囊胚移植的活产率相似(40% vs 53.3%),五次移植后累积活产率达98.1%(95% CI=96.5-99.6%)。
要点
- 三次整倍体囊胚移植失败后,第四次与第五次移植活产率分别为40%和53.3%,无显著差异。
- 五次整倍体囊胚移植后累积活产率为98.1%(95% CI=96.5-99.6%)。
- 作者认为着床失败似乎主要源于胚胎因素,不明原因复发性着床失败患病率应低于2%。
核心结论
- 第四次和第五次整倍体囊胚移植的活产率相似,分别为40%和53.3%,五次整倍体囊胚移植后累积活产率为98.1%(95% CI=96.5-99.6%)。
- 作者认为着床失败似乎主要由于胚胎因素,不明原因复发性着床失败的患病率应低于2%。
- 在排除已知的着床失败病因后,再进行一次胚胎移植可能是最好的下一步(作者观点)。
研究设计与样本
- 国际多中心回顾性研究,在25家个体诊所开展,研究期间为2012年1月至2022年12月。
- 共筛查123987例患者、总计64572次整倍体囊胚移植。
- 排除标准包括:在其他诊所曾有胚胎移植史、在参与诊所曾有未筛查胚胎移植史、父母核型异常、使用供卵或代孕、未治疗的宫腔内病变(如息肉、肌瘤)、先天性子宫异常、子宫腺肌病、交通性输卵管积水、开始孕酮前内膜厚度<6 mm、男方非梗阻性无精子症使用睾丸精子、移植 reported 中间型染色体拷贝数(即嵌合)胚胎、单基因病或结构染色体异常的胚胎植入前遗传学检测周期。
- 卵巢刺激方案和胚胎学实验室操作(包括滋养外胚层活检)遵循各中心常规实践;囊胚倍性状态通过综合染色体筛查确定;内膜准备方案遵循参与中心常规实践,包括程序化周期、自然或改良自然周期。
主要发现
- 共105例患者(占总人群0.085%)符合标准,在连续三次整倍体囊胚移植未获阳性妊娠试验后接受至少一次额外整倍体囊胚移植。
- 第四次和第五次整倍体囊胚移植的活产率相似(40% vs 53.3%,相对风险=1.33,95% CI=0.93-1.9,P值=0.14)。
- 敏感性分析排除受精后第7天活检的囊胚、BMI>30 kg/m2的女性、使用非射精或供精的周期、双胚胎移植周期以及因内膜容受性检测结果修改移植日的周期后,结果相似。
- 在有数据的情况下,第四次整倍体囊胚移植的活产率与第一次相似(相对风险=0.84,95% CI=0.58-1.21,P=0.29)。
- 五次整倍体囊胚移植后累积活产率为98.1%(95% CI=96.5-99.6%)。
关键数值与推荐
- 第四次与第五次整倍体囊胚移植活产率:40% vs 53.3%(相对风险=1.33,95% CI=0.93-1.9,P=0.14)。
- 第四次整倍体囊胚移植与第一次整倍体囊胚移植活产率比较:相对风险=0.84(95% CI=0.58-1.21,P=0.29)。
- 五次整倍体囊胚移植后累积活产率:98.1%(95% CI=96.5-99.6%)。
- 前三次整倍体囊胚移植提供累积活产率92.6%。
临床怎么用
- 在排除已知的着床失败病因后,再进行一次胚胎移植可能是最好的下一步(作者观点)。
- 作者认为着床失败似乎主要由于胚胎因素,不明原因复发性着床失败患病率应低于2%。
局限性
- 回顾性设计有其固有局限性。
- 继续接受进一步整倍体胚胎移植的患者与三次整倍体移植失败后退出治疗的患者可能存在系统性差异,也许在卵巢储备或经济状况方面。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the clinical pregnancy and live birth rates in women who underwent up to two more euploid blastocyst transfers after three failures in the absence of another known factor that affects implantation? SUMMARY ANSWER: The fourth and fifth euploid blastocyst transfers resulted in similar live birth rates of 40% and 53.3%, respectively, culminating in a cumulative live birth rate of 98.1% (95% CI = 96.5-99.6%) after five euploid blastocyst transfers. WHAT IS KNOWN ALREADY: The first three euploid blastocysts have similar implantation and live birth rates and provide a cumulative live birth rate of 92.6%. STUDY DESIGN, SIZE, DURATION: An international multi-center retrospective study was conducted at 25 individual clinics. The study period spanned between January 2012 and December 2022. A total of 123 987 patients with a total of 64 572 euploid blastocyst transfers were screened for inclusion. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients with a history of any embryo transfer at another clinic, history of any unscreened embryo transfer at participating clinics, parental karyotype abnormalities, the use of donor oocytes or a gestational carrier, untreated intracavitary uterine pathology (e.g. polyp, leiomyoma), congenital uterine anomalies, adenomyosis, communicating hydrosalpinx, endometrial thickness <6 mm prior to initiating of progesterone, use of testicular sperm due to non-obstructive azoospermia in the male partner, transfer of an embryo with a reported intermediate chromosome copy number (i.e. mosaic), preimplantation genetic testing cycles for monogenic disorders, or structural chromosome rearrangements were excluded. Ovarian stimulation protocols and embryology laboratory procedures including trophectoderm biopsy followed the usual practice of each center. The ploidy status of blastocysts was determined with comprehensive chromosome screening. Endometrial preparation protocols followed the usual practice of participating centers and included programmed cycles, natural or modified natural cycles. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 105 (0.085% of the total population) patients met the criteria and underwent at least one additional euploid blastocyst transfer after failing to achieve a positive pregnancy test with three consecutive euploid blastocyst transfers. Outcomes of the fourth and fifth euploid blastocyst transfers were similar across participating centers. Overall, the live birth rate was similar with the fourth and fifth euploid blastocysts (40% vs 53.3%, relative risk = 1.33, 95% CI = 0.93-1.9, P value = 0.14). Sensitivity analyses excluding blastocysts biopsied on Day 7 postfertilization, women with a BMI >30 kg/m2, cycles using non-ejaculate or donor sperm, double-embryo transfer cycles, and cycles in which the day of embryo transfer was modified due to endometrial receptivity assay test result yielded similar results. Where data were available, the fourth euploid blastocyst had similar live birth rate with the first one (relative risk = 0.84, 95% CI = 0.58-1.21, P = 0.29). The cumulative live birth rate after five euploid blastocyst transfers was 98.1% (95% CI = 96.5-99.6%). LIMITATIONS, REASONS FOR CAUTION: Retrospective design has its own inherent limitations. Patients continuing with a further euploid embryo transfer and patients dropping out from treatment after three failed euploid transfers can be systematically different, perhaps with regard to ovarian reserve or economic status. WIDER IMPLICATION OF THE FINDINGS: Implantation failure seems to be mainly due to embryonic factors. Given the stable and high live birth rates up to five euploid blastocysts, unexplained recurrent implantation failure should have a prevalence of <2%. Proceeding with another embryo transfer can be the best next step once a known etiology for implantation failure is ruled out. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: N/A.
引用
- Gill P, Ata B, Arnanz A, et al. Does recurrent implantation failure exist? Prevalence and outcomes of five consecutive euploid blastocyst transfers in 123 987 patients. Hum Reprod. 2024. PMID: 38452358. doi:10.1093/humrep/deae040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。